B. Riley Has Negative Forecast for CRBP Q2 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at B. Riley reduced their Q2 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a report released on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings of ($1.63) per share for the quarter, down from their prior forecast of ($0.92). B. Riley has a “Buy” rating on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

A number of other equities analysts also recently commented on the stock. William Blair started coverage on shares of Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an “outperform” rating for the company. Oppenheimer reduced their target price on Corbus Pharmaceuticals from $60.00 to $56.00 and set an “outperform” rating on the stock in a research report on Wednesday. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Royal Bank of Canada dropped their target price on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, Jefferies Financial Group dropped their price objective on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.88.

Corbus Pharmaceuticals Trading Down 3.0 %

Shares of NASDAQ:CRBP opened at $6.45 on Friday. The company has a market capitalization of $78.90 million, a PE ratio of -1.38 and a beta of 3.19. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $61.90. The business’s fifty day simple moving average is $6.33 and its 200-day simple moving average is $10.81.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.13).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC grew its stake in shares of Corbus Pharmaceuticals by 215.0% during the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company’s stock worth $4,563,000 after purchasing an additional 263,902 shares during the period. Orbimed Advisors LLC increased its holdings in Corbus Pharmaceuticals by 28.5% in the fourth quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company’s stock valued at $13,833,000 after buying an additional 259,735 shares in the last quarter. Altium Capital Management LLC increased its holdings in Corbus Pharmaceuticals by 97.4% in the fourth quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company’s stock valued at $4,543,000 after buying an additional 190,000 shares in the last quarter. Prosight Management LP boosted its stake in shares of Corbus Pharmaceuticals by 107.7% during the 4th quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company’s stock worth $3,186,000 after acquiring an additional 140,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Corbus Pharmaceuticals by 769.4% during the 4th quarter. Renaissance Technologies LLC now owns 139,100 shares of the biopharmaceutical company’s stock valued at $1,641,000 after acquiring an additional 123,100 shares during the period. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.